Clinical Edge Journal Scan

Multiple sclerosis: Cognitive impairment worsens during the pre- and postrelapse period


 

Key clinical point: Cognitive impairments may be evaluated up to 30 days before and up to 550 days after a relapse, beyond which they revert to prerelapse levels in patients with relapsing-remitting multiple sclerosis (RRMS).

Major finding: From 30 days prerelapse to 550 days postrelapse, there was a significant drop in the Symbol Digit Modalities Test (SDMT) score, with the largest decline occurring at 0-30 days postrelapse (β-coefficient, −4.00; 95% CI, −4.61 to −3.39) compared with the period of remission.

Study details: This nationwide cohort study recorded 31,529 SDMTs from among 3,877 patients with incident RRMS, each having a minimum of 2 SDMT scores recorded.

Disclosures: This study was funded by a postdoctoral fellowship award to KA McKay from the Swedish Research Council for Health, Working Life, and Welfare (Forte). The authors reported no conflict of interests.

Source: McKay KA et al. Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26301 .

Recommended Reading

Certain DMTs in MS linked to more psoriasis
ICYMI Multiple Sclerosis
Multiple DMTs linked to alopecia, especially in women
ICYMI Multiple Sclerosis
New consensus guideline on clinical MRI use in MS
ICYMI Multiple Sclerosis
Cannabis use common for MS-related spasticity
ICYMI Multiple Sclerosis
Specialty pharmacists may speed time to MS treatment
ICYMI Multiple Sclerosis
Brief, automated cognitive test may offer key advantages in MS
ICYMI Multiple Sclerosis
B-cell repletion is common with MS drug, but no symptom worsening
ICYMI Multiple Sclerosis
COVID-19 vaccination safe and effective in patients with multiple sclerosis
ICYMI Multiple Sclerosis
Risk factors for disease reactivation after natalizumab cessation in multiple sclerosis
ICYMI Multiple Sclerosis
Multiple sclerosis: Interferon therapy boosts humoral response following SARS-CoV-2 vaccination
ICYMI Multiple Sclerosis